Montana’s plan to become an experimental medical hub just pushed forward
Montana challenges federal drug regulations by establishing a rapid approval path for experimental biotech treatments.
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board...
MIT Technology Review
Source

Generated insight by OnAirToday AI
Montana's new regulatory framework effectively bypasses traditional federal oversight by creating a fast-track pathway for experimental drugs. This move could spark a massive surge in biotech innovation while simultaneously raising significant concerns regarding patient safety and clinical efficacy standards.

Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.